LIFE studyReducción de la HVI siguiendo criterios ECG

• Losartan reduce la HVI significativamente mas que Atenolol con una disminución similar de la T.A.

-18

-16

-14

-12

-10

-8

-6

-4

-2

0

Cornell Product

Sokolow-Lyon

(%) Cambios respecto del basal

Losartan 50–100 mg

Atenolol 50–100 mg

Pɘ.0001

Pɘ.0001

Dahlöf et al. Lancet 2002;359:995–1003

Diapositiva anterior

Diapositiva siguiente

Ir a la primera diapositiva

Ver versión gráfica

One of the key results of the LIFE study was a significantly greater reduction in ECG-detected LVH with losartan-based therapy than with atenolol-based therapy despite similar reductions in BP.1

The importance of LVH reduction is illustrated by the fact that losartan-based treatment also prevented more cardiovascular morbidity and deaths than the one based on atenolol.

1. Dahlöf B, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003.